Cargando…

Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis

IMPORTANCE: Conventional meta-analyses with aggregated study-level data have yielded conflicting results for the comparative effectiveness of tenofovir disoproxil fumarate vs entecavir in reducing hepatocellular carcinoma (HCC) risk among patients with chronic hepatitis B virus. Within-study heterog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Darren Jun Hao, Ng, Cheng Han, Tay, Phoebe Wen Lin, Syn, Nicholas, Muthiah, Mark D., Lim, Wen Hui, Tang, Ansel Shao Pin, Lim, Kai En, Lim, Grace En Hui, Tamaki, Nobuharu, Kim, Beom Kyung, Teng, Margaret Li Peng, Fung, James, Loomba, Rohit, Nguyen, Mindie H., Huang, Daniel Q.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244612/ https://www.ncbi.nlm.nih.gov/pubmed/35767258 http://dx.doi.org/10.1001/jamanetworkopen.2022.19407

Ejemplares similares

868: PREVENTING HEPATCELLULAR CARCINOMA WITH TENOFOVIR VS ENTECAVIR: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF PROPENSITY SCORE MATCHED STUDIES
por: Tan, Darren J., et al.
Publicado: (2022)

Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials
por: Tan, Darren Jun Hao, et al.
Publicado: (2023)

Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis
por: Lee, Hyo-Young, et al.
Publicado: (2019)

Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
por: Ishido, Shun, et al.
Publicado: (2023)

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
por: Lee, Sung Won, et al.
Publicado: (2021)

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis
por: Tan, Darren Jun Hao, et al.
Publicado: (2022)

Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis
por: Tan, Darren Jun Hao, et al.
Publicado: (2022)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia
por: Xiao, Jieling, et al.
Publicado: (2022)

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
por: Tamaki, Nobuharu, et al.
Publicado: (2019)

Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection
por: Li, Pengpeng, et al.
Publicado: (2023)

Entecavir‐induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide
por: Lim, I. Vern, et al.
Publicado: (2023)

Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir
por: Lim, Jung Hyun, et al.
Publicado: (2021)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
por: Yang, Young-Mo, et al.
Publicado: (2017)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020)

Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis
por: Cheung, Ka Shing, et al.
Publicado: (2020)

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
por: Kim, David Sooik, et al.
Publicado: (2019)

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
por: Huang, Chih-Wen, et al.
Publicado: (2023)

Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy
por: Shen, Junyi, et al.
Publicado: (2022)

Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality
por: Ng, Cheng Han, et al.
Publicado: (2022)

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment
por: Ma, Te-Ling, et al.
Publicado: (2019)

Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse
por: Tseng, Tzu-Ning, et al.
Publicado: (2022)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation
por: Hu, Zili, et al.
Publicado: (2022)

Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
por: Park, Jihye, et al.
Publicado: (2017)

Tenofovir over Entecavir on Hepatocellular Carcinoma Prevention: Potential Mechanisms and Suitable Population
por: Huang, Yongfa, et al.
Publicado: (2022)

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases
por: Tamaki, Nobuharu, et al.
Publicado: (2021)

Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B
por: Chang, Te-Sheng, et al.
Publicado: (2021)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

Effects of viral load on tenofovir vs. entecavir efficacy in recurrence prevention of hepatitis B virus-related hepatocellular carcinoma
por: Qi, Weili, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals
por: Tang, Ansel Shao Pin, et al.
Publicado: (2022)

Foregut bypass vs. restrictive bariatric procedures for nonalcoholic fatty liver disease: a meta-analysis of 3,355 individuals
por: Lim, Wen Hui, et al.
Publicado: (2022)

Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients
por: Cho, Eun Ju, et al.
Publicado: (2015)

Virologic Response and Safety of Tenofovir Versus Entecavir in Treatment-Naïve Chronic Hepatitis B patients
por: Yu, Hyung Min, et al.
Publicado: (2015)

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
por: Kim, Jeong Han, et al.
Publicado: (2016)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
por: Jeon, Hee-Jeong, et al.
Publicado: (2017)

Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
por: Ha, Yeonjung, et al.
Publicado: (2020)

Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B
por: Tang, Kaiyue, et al.
Publicado: (2023)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients
por: Lai, Rui-Min, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rkrp39683mlnt7p3tg8f0opdjc